Interleukin-6 as a therapeutic target in candidate inflammatory diseases

Our plain-English summary of Interleukin-6 as a therapeutic target in candidate inflammatory diseases, by N. Nishimoto (Clinical Pharmacology and Therapeutics, 2010).

The study

• Author: N. Nishimoto
• Journal: Clinical Pharmacology and Therapeutics
• Published: 2010;87(4):483-7
• Type of article: Review
• Cited by: 99 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Abstract

Interleukin (IL)-6 is a multifunctional cytokine that regulates immune response, inflammation, and hematopoiesis. Although IL-6 plays several important physiological roles, deregulated overproduction of IL-6 causes various clinical symptoms and abnormalities in laboratory test results. Overproduction of IL-6 has been shown to underlie a number of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA), systemic-onset juvenile idiopathic arthritis (soJIA), and Castleman's disease, as well as malignancies such as multiple myeloma and mesothelioma. Blocking of IL-6 signaling may be therapeutic in diseases characterized by pathological IL-6 overproduction. This review provides an overview of IL-6 as a therapeutic target in candidate inflammatory diseases.

In plain English

This article was a short review. It reported no new research and did not study asbestos exposure. It reviewed published research on interleukin-6 (IL-6), an inflammation-related signaling protein, and on drugs that block it, mainly tocilizumab. It described trials showing tocilizumab was effective in rheumatoid arthritis, including in patients who had responded poorly to other drugs. Infections were the most common class of side effects, and a rise in cholesterol was frequently reported. It also described benefits in systemic-onset juvenile idiopathic arthritis and Castleman's disease, for which the drug was approved in Japan. Mesothelioma came up only briefly. The author wrote that IL-6 acts as a growth factor, or helps cancer cells avoid normal cell death, in several cancers including mesothelioma, and suggested that, from the viewpoint of inflammatory symptoms, mesothelioma may be a good candidate for IL-6 inhibition. No treatment study in mesothelioma was described. The author concluded that IL-6 inhibition has a wide array of therapeutic applications. The author noted that for some conditions the available data were too limited for an accurate assessment.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review
• Who was studied: No study population of its own. Single author, Laboratory of Immune Regulation, Wakayama Medical University, Japan. The review drew on published clinical trials and case reports of IL-6-blocking drugs in rheumatoid arthritis, juvenile idiopathic arthritis, Castleman's disease, Crohn's disease, multiple myeloma and other conditions.
• Exposure: Not an asbestos exposure study. The subject was drugs that block IL-6 or its receptor: tocilizumab, BE-8, CNTO-328, CNTO-136, REGN-88 and ALD518, listed in the article's Table 1.
• Main results:
  • The review stated that IL-6 acts as a growth factor or antiapoptotic factor in various cancers, including multiple myeloma, mesothelioma and renal cell carcinoma.
  • The author suggested that, from the viewpoint of inflammatory manifestations, mesothelioma and pancreas cancer may be good candidates for IL-6 inhibition. This was a suggestion. The review described no treatment study in mesothelioma, and mesothelioma does not appear among the candidate diseases in Table 1.
  • According to the published trials reviewed, tocilizumab, alone or with methotrexate, was shown to be effective in rheumatoid arthritis patients who had an insufficient response to methotrexate, other disease-modifying antirheumatic drugs, or TNF inhibitors.
  • Safety: infections were the most common class of adverse events with tocilizumab.
  • Safety: an increase in serum cholesterol was frequently reported in every clinical trial.
  • In multicentric Castleman's disease, BE-8 and tocilizumab markedly relieved clinical symptoms. Tocilizumab was approved in Japan as an orphan drug for Castleman's disease in April 2005.
  • Tocilizumab was approved in Japan for systemic-onset juvenile idiopathic arthritis in April 2008, on the basis of clinical trial results.
• The authors' conclusion: The author concluded that, because IL-6 has diverse biological functions, inhibiting it has a wide array of therapeutic applications.
• Limitations the authors state:
  • For vasculitis and the inherited inflammatory syndromes discussed, such as CINCA syndrome, the available data were too limited to assess how well tocilizumab works.
  • There was no evidence on whether it is better to block IL-6 itself or its receptor.

Topics

Medical terms in this study, explained in our Lexicon: Cytokine, Inflammation, Idiopathic, Myeloma, Mesothelioma.

Related studies

• The CUL4A ubiquitin ligase is a potential therapeutic target in skin cancer and other malignancies — J. Hannah, P.B. Zhou (2013)
• Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy — H. Bielefeldt-Ohmann, A.L. Marzo, et al. (1995)
• CD157: From immunoregulatory protein to potential therapeutic target — E. Ortolan, S. Augeri, et al. (2019)
• Early life exposure to environmental tobacco smoke alters immune response to asbestos via a shift in inflammatory phenotype resulting in increased disease development — T.A. Brown, A. Holian, et al. (2016)
• EphB4 as a therapeutic target in mesothelioma — R. Liu, B.D. Ferguson, et al. (2013)
• KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma — S. Cregan, L. McDonagh, et al. (2016)

Browse return to medical research.